McKee K T, Huggins J W, Trahan C J, Mahlandt B G
Disease Assessment Division, U.S. Army Medical Research, Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21701-5011.
Antimicrob Agents Chemother. 1988 Sep;32(9):1304-9. doi: 10.1128/AAC.32.9.1304.
Junin virus-infected rhesus macaques received prophylactic and therapeutic ribavirin to assess the potential of this drug for treating humans with Argentine hemorrhagic fever. When ribavirin was administered intramuscularly at the time of experimental infection with the lethal P3790 strain of Junin virus, all animals were protected from clinical disease. A delay in the initiation of therapy until after the onset of illness resulted in improvement and resolution of systemic signs of disease; however, survivors subsequently developed a late-onset central nervous system infection which was fatal in two of three animals. Side effects of ribavirin included thrombocytosis and severe anemia, both of which resolved promptly on withdrawal of drug therapy. Results of this study suggest that ribavirin may prove useful in treating humans with Argentine hemorrhagic fever.
感染胡宁病毒的恒河猴接受了预防性和治疗性利巴韦林治疗，以评估该药物治疗阿根廷出血热患者的潜力。当在实验性感染致死性胡宁病毒P3790株时肌肉注射利巴韦林，所有动物均免受临床疾病侵害。治疗开始延迟至发病后，疾病的全身症状得到改善并消退；然而，幸存者随后出现迟发性中枢神经系统感染，三只动物中有两只死亡。利巴韦林的副作用包括血小板增多症和严重贫血，停药后这两种情况均迅速缓解。本研究结果表明，利巴韦林可能对治疗阿根廷出血热患者有用。
